Please assess the completion status of the following clinical trial:

Trial Title: Effects of Substance P Antagonists on Adrenal Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects;~* Age ranging 18 - 30 years old;~* Submitted to a social security regimen;~* Agreeing to the study \& Informed consent form signed;~* Body mass index (\[weight (kg)/height (m)\]²) \< 27;~* No treatment received 6 weeks before inclusion;~* No anomaly after: complete clinical examination, pulse and blood pressure measurement, ECG;~* No biological abnormality after the following biological testing:~  * Hematology: white \& red blood cells \& platelets count, haemoglobin, hematocrit~ * Blood biochemistry: sodium, potassium, chloride, bicarbonate, creatinine, urea~ * Urinary biochemistry (24 h collection): cortisol, aldosterone~ * Serologies: HIV, HBV, HCV~* No participation in a clinical trial 3 months before inclusion.~Exclusion Criteria:~* Subject not agreeing to the study or impossible to follow-up;~* Known history of significant medical or surgical pathology, notably endocrine;~* Renal or hepatic insufficiency;~* Nephrotic syndrome;~* Edematous syndrome;~* Hypertension or postural hypotension;~* Cardiac rhythm or conduction pathologies;~* Cardiac insufficiency;~* Epilepsy;~* Significant psychiatric disorder;~* Known history of severe allergy, hypersensitivity to aprepitant ant/or metoclopramide;~* Hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficit;~* Impaired lactose tolerance.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Aprepitant (Type: EXPERIMENTAL): 7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
- placebo (Type: PLACEBO_COMPARATOR): 7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.

Based on this trial design, predict the completion outcome and termination type (if applicable).